Pharmasset, Inc. Company Profile

22:29 EST 22nd November 2014 | BioPortfolio

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeutics for the treatment of human immunodeficiency virus, or HIV, hepatitis B virus, or HBV, and hepatitis C virus, or HCV. Our research and development efforts focus on a class of compounds known as nucleoside analogs, which act to inhibit the natural enzymes required for viral replication.


303-A College Road East
New Jersey
United States of America


Phone: (609) 613-4100
Fax: (609) 613-4150

News Articles [11 Associated News Articles listed on BioPortfolio]

Speculators On The Next HCV Acquisition Should Not Overlook Technological Platforms

ByAustrolib:Merck's (MRK) acquisition of Idenix (IDIX) for its hepatitis C [HCV] platform has certainly created a storm of chatter in the investment community. 12 articles have been published on Seeki...

Gilead claims victory in Sovaldi arbitration

Gilead Sciences Inc. (NASDAQ:GILD) disclosed in an SEC filing that an arbitration panel ruled Roche (SIX:ROG; OTCQX:RHHBY) failed to establish its claims to Gilead's HCV drug Sovaldi sofosbuvir. Roche...

OnCore performance

Ebb & Flow OnCore performance After helping to develop blockbuster HCV drug Sovaldi sofosbuvir, a team of ex-Pharmasset Inc. executives now have lined up money and assets in OnCore Biopharma Inc. and ...

Senators push for details on Sovaldi's cost

Two members of the Senate Finance Committee requested pricing information for HCV drug Sovaldi sofosbuvir from Gilead Sciences Inc. (NASDAQ:GILD), including an explanation of the difference between th...

Senate Finance Committee Probing Prices For Hepatitis C Drug

Sens. Ron Wyden, D-Ore., and Charles Grassley, R-Iowa, send letter to the drug's maker requesting information about how it set the price, which runs about $84,000 for a standard three-month regimen. T...

OnCore adds to HBV pipeline with Enantigen

HBV play OnCore Biopharma Inc. (Doylestown, Pa.) acquired infectious disease company Enantigen Therapeutics Inc. (Doylestown, Pa.) in an all-cash deal of undisclosed size. OnCore gains two HBV program...

Buy The Dip In Gilead: Why A Decrease In Quarterly Sovaldi Revenue Is Expected

By Pharma Doc: Introduction: Gilead (NASDAQ:GILD) is an innovative biotech company that has continued to provide superior innovation leading to transformational drugs primarily in antivirals (HIV). ...

AHF to Gilead: “Have You No Shame?” Pricing New Hepatitis C Drug Above $84K

Gilead will price the first all-oral treatment for the virus, to hit the market in October, above the current $84,000 Sovaldi formulation, which is prescribed and taken with ribav...

Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

Pharmasset, Inc.

We are a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Our primary focus is on the development of oral therapeut...

More Information about "Pharmasset, Inc." on BioPortfolio

We have published hundreds of Pharmasset, Inc. news stories on BioPortfolio along with dozens of Pharmasset, Inc. Clinical Trials and PubMed Articles about Pharmasset, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Pharmasset, Inc. Companies in our database. You can also find out about relevant Pharmasset, Inc. Drugs and Medications on this site too.

Search BioPortfolio:

Relevant Topic

Top five promising drugs Phase I (November 2013)
Latest News Clinical Trials Research Drugs Reports Corporate
THE FIVE MOST PROMISING DRUGS ENTERING PHASE I TRIALS Drug Disease Company ARC-520 Hepatitis B virus infection Arrowhead Research GR-MD-02 Non-alcoholic steatohepatitis ...


Corporate Database Quicklinks

Searches Linking to this Company Record